BioNTech SE American Depositary Share
BNTXDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 17, 2022 | $2.13 | 2022-06-02 | 2022-06-03 |
Dividends Summary
- Consistent Payer: BioNTech SE American Depositary Share has rewarded shareholders with 1 dividend payments over the past 0 years.
- Total Returned Value: Investors who held BNTX shares during this period received a total of $2.13 per share in dividend income.
- Latest Payout: The most recent dividend of $2.13/share was paid 1492 days ago, on June 17, 2022.
Company News
The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the h...
Pfizer and Bristol Myers Squibb are presented as attractively valued dividend stocks despite recent challenges. Both pharmaceutical companies face patent cliffs but have strong pipelines with promising candidates in oncology, weight loss, and anticoagulants. With forward yields of 7.1% and 4.3% respectively, and trading at discounted valuations (...
BioNTech and Bristol Myers Squibb announced interim results from the ROSETTA Lung-02 Phase 2/3 study showing that their bispecific PD-L1xVEGF-A immunomodulator candidate Pumitamig demonstrated encouraging anti-tumor activity in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC). The drug showed confirmed objective respo...
BioNTech and Bristol Myers Squibb announced interim Phase 2 data from the ROSETTA Lung-02 trial showing that their investigational bispecific immunomodulator pumitamig combined with chemotherapy demonstrated encouraging anti-tumor activity in first-line non-small cell lung cancer, with confirmed objective response rates of 63.6% in non-squamous a...
BioNTech will present clinical data at ASCO 2026 showing encouraging anti-tumor activity for pumitamig in combination with chemotherapy across multiple cancer types, and positive overall survival data for gotistobart in platinum-resistant ovarian cancer. The company is advancing 25+ Phase 2/3 trials including 13 pivotal trials across its diversif...
